Pharmaceutical

JURA Bio and Syena partner to develop TCR-based therapies

JURA Bio has entered into a research collaboration with Replay cell therapy product company Syena for the development of TCR based therapies.

Sep 23, 2023 - 20:00
JURA Bio and Syena partner to develop TCR-based therapies
JURA Bio has entered into a research collaboration with Replay cell therapy product company Syena for the development of TCR based therapies.
Read the original article

Tags:

Previous Article

Alvotech’s AVT05 in phase III rheumatoid arthritis study, as the sole candidate

Next Article

Signal: CMR Surgical Raises $165m to continue development of surgical robot

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

South Korean company Dong-A ST wins FDA approval for Stelara biosimilar

South Korean company Dong-A ST wins FDA approval for St...

Oct 12, 2024

STAT+: U.K. researchers warn about biases in medical devices, health care algorithms

STAT+: U.K. researchers warn about biases in medical de...

Mar 12, 2024

INCB-57643 by Incyte for Myelofibrosis: Likelihood of A...

Feb 8, 2024